Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Ravi Vij, Suvina Amin, Jin Gu, Thomas S. Marshall, Susan Fish, Sujith Dhanasiri, Gabriela Hernandez, David Cella, Hartmut Goldschmidt, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2023-178500

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Nina Shah, Ravi Vij, Jenna S. Roberts, Ivana Rajkovic, Rebecca Silbermann, Jens Hillengass, Sujith Dhanasiri, Julia Braverman, Abigail McMillan, Devender Dhanda

Blood (2022) 140 (Supplement 1): 13259–13261.

https://doi.org/10.1182/blood-2022-158235

Published: 2022

Journal Articles

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Michele Cavo, Sujith Dhanasiri, Valerio De Stefano, Angel Ramírez Payer, Martin Wiesholzer, Yvonne Tromp, Meegahage Ratnakanthi Perera, Valentine Richez-Olivier, Maciej Gil, David Bernasconi, Barbara Gamberi

Blood (2022) 140 (Supplement 1): 7195–7196.

https://doi.org/10.1182/blood-2022-162493

Published: 2022

Journal Articles

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Karthik Ramasamy, Niels Abildgaard, Marie-Christiane Vekemans, Barbara Gamberi, Angel Ramírez Payer, Gillian Millar, Annalisa Ansaloni, Margaret Atiba-Davies, David Bernasconi, Torben Plesner, Sujith Dhanasiri

Blood (2022) 140 (Supplement 1): 10000–10001.

https://doi.org/10.1182/blood-2022-162529

Published: 2022

Journal Articles

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

Michel Delforge, Nina Shah, MD, Paula Rodriguez-Otero, Parameswaran Hari, MD MRCP, Julia Braverman, PhD, Andrew Trigg, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136677

Published: 2020

Journal Articles

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Nina Shah, MD, Dieter Ayers, Faith E. Davies, Shannon Cope, Ali Mojebi, Kejal Parikh, Devender Dhanda, Parameswaran Hari, MD MRCP, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136730

Published: 2020

Journal Articles

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Katja C. Weisel, MD, Sujith Dhanasiri, Aline Gauthier, Amie Padhiar, Eva Casal, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 2201.

https://doi.org/10.1182/blood-2019-123639

Published: 2019

Journal Articles

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Elena Zamagni, MD, Sujith Dhanasiri, Adam Moore, Arun Ghale, Murielle Roussel, MD

Blood (2019) 134 (Supplement_1): 4772.

https://doi.org/10.1182/blood-2019-123629

Published: 2019

Journal Articles

Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis

Michael Sebag, MD PhD, Julie Stakiw, MD, Thomas J. Stephens, Amie Padhiar, Tony Kim, Jane Shum, Sujith Dhanasiri, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 70.

https://doi.org/10.1182/blood-2019-123636

Published: 2019

Journal Articles

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Michele Cavo, Valerio De Stefano, MD, Angel Ramirez Payer, Martin Wiesholzer, Yvonne Tromp, Gaëtan Vanstraelen, Baerbel Schaedlich, Richez Valentine, Sujith Dhanasiri, Elisabeth Kueenburg, Barbara Rosettani, Claire Martin, Stefano Pozzi, Pamela Bacon, Barbara Gamberi

Blood (2019) 134 (Supplement_1): 5580.

https://doi.org/10.1182/blood-2019-124555

Published: 2019

Journal Articles

Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands

Carin A. Uyl-de Groot, Rachel Ramsden, Janneke Boersma, Sonja Zweegman, MD PhD, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 3555.

https://doi.org/10.1182/blood-2018-99-112826

Published: 2018

Journal Articles

Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)

Philip L. McCarthy, MD, Paul Richardson, Vera Suman, Miranda Cooper, Owain Saunders, Sujith Dhanasiri, Sergio Giralt, MD, Kenneth Anderson, MD, Edward Stadtmauer, Sarah A. Holstein, MD PhD

Blood (2018) 132 (Supplement 1): 4737.

https://doi.org/10.1182/blood-2018-99-113001

Published: 2018

Journal Articles

Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis

Karthik Ramasamy, Howard Thom, Vijay K. D'Souza, Vanessa Buchanan, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 4744.

https://doi.org/10.1182/blood-2018-99-112882

Published: 2018

Journal Articles

Cost-Effectiveness of Newly Emerging Regimens for Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Autologous Stem Cell Transplantation (ASCT) Compared with the Current Standards of Care in EU5

John Ashcroft, Callum Shephard, Ashlie Elnoursi, Christopher Pelligra, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2018-99-118349

Published: 2018

Journal Articles

Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)

Neil Hawkins, Karthik Ramasamy, Sujith Dhanasiri

Blood (2018) 132 (Supplement 1): 2013.

https://doi.org/10.1182/blood-2018-99-111804

Published: 2018

Journal Articles

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, Aurore Perrot, Denis Caillot, Margaret Macro, Bertrand Arnulf, Karim Belhadj, Laurent Garderet, Thierry Facon, Shien Guo, Arman Altincatal, Sujith Dhanasiri, Xavier Leleu, MD PhD, Philippe Moreau, Michel Attal

Blood (2018) 132 (Supplement 1): 716.

https://doi.org/10.1182/blood-2018-99-111477

Published: 2018

Journal Articles

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Jason Tay, MD FRCPC, Ravi Vij, MDMBA, Maxim Norkin, MD, Shaji K Kumar, MD, Tamila L Kindwall-Keller, DO, Jenna S Roberts, PhD, Darrell J White, MD, Robert P Wood, BSc, Sophee E Blanthorn-Hazell, MSc, BSc, Adriana C. Rossi, MDMSc, Sujith Dhanasiri, MSc, Faiza Zafar, MPAS, Kim Newhouse, BSc. , BScN, McCurdy R Arleigh, MD MHA, FRCPC

Blood (2017) 130 (Supplement 1): 2150.

https://doi.org/10.1182/blood.V130.Suppl_1.2150.2150

Published: 2017

Journal Articles

Assessing Outcomes, Healthcare Resource Utilisation and Costs across Europe in Newly Diagnosed Multiple Myeloma (NDMM) Patients Post Autologous Stem Cell Transplant (ASCT)

John Ashcroft, Davneet Judge, Sujith Dhanasiri, MSc, Gavin Taylor-Stokes

Blood (2017) 130 (Supplement 1): 4709.

https://doi.org/10.1182/blood.V130.Suppl_1.4709.4709

Published: 2017

Journal Articles

A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant

Susanne Schmitz, Vanessa Buchanan, Joy Leahy, Sujith Dhanasiri, MSc, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, John Ashcroft

Blood (2017) 130 (Supplement 1): 1832.

https://doi.org/10.1182/blood.V130.Suppl_1.1832.1832

Published: 2017

Journal Articles

Lenalidomide Maintenance Therapy Post-Autologous Stem Cell Transplant: A Healthcare Cost-Impact Analysis in Europe

Graham Jackson, MDPhD, Richard Dutton, Elena Zamagni, MD, Rowena Hughes, Sujith Dhanasiri, MSc

Blood (2017) 130 (Supplement 1): 3405.

https://doi.org/10.1182/blood.V130.Suppl_1.3405.3405

Published: 2017

NARROW

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Efficacy of Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Post-Lenalidomide: Results from a Systematic Literature Review and Indirect Treatment Comparison

Patient Characteristics, Treatment Outcomes and Healthcare Resource Utilization across Europe in Multiple Myeloma Patients Ineligible for Stem Cell Transplantation Who Received Lenalidomide- or Bortezomib-Based Regimens

Lenalidomide Plus Bortezomib and Dexamethasone in the Treatment of Newly Diagnosed Multiple Myeloma: Results from a Canadian Cost-Effectiveness Analysis

Safety Profile for Lenalidomide-Based and Non-Lenalidomide-Based First-Line Therapy for Multiple Myeloma in Transplant Ineligible Patients: Real-World Evidence from a European Post-Authorization Safety Study

Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands

Survival Analysis from the CALGB Study of Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation Adjusted for Crossover (Alliance 100104)

Relative Efficacy of Treatment Options in Newly Diagnosed Multiple Myeloma: Results from a Systematic Literature Review and Network Meta-Analysis

Cost-Effectiveness of Newly Emerging Regimens for Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Autologous Stem Cell Transplantation (ASCT) Compared with the Current Standards of Care in EU5

Estimating the Effect of Individual Agents in the Treatment of Relapsed, Refractory Multiple Myeloma (RRMM)

The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial

Impact of Active Maintenance Treatment (MT) Compared to No MT on the Quality of Life (QoL) of Patients with Multiple Myeloma (MM) Following First Autologous Stem Cell Transplant (ASCT)

Assessing Outcomes, Healthcare Resource Utilisation and Costs across Europe in Newly Diagnosed Multiple Myeloma (NDMM) Patients Post Autologous Stem Cell Transplant (ASCT)

A Systematic Review and Network Meta-Analysis of Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplant

Lenalidomide Maintenance Therapy Post-Autologous Stem Cell Transplant: A Healthcare Cost-Impact Analysis in Europe

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only